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Antineoplastic agents may be very effective in the first round
of combination chemotherapy; however, upon subsequent
treatment, many tumours display resistance. In many in-
stances, drug resistance is observed to multiple agents which
differ in structure as well as in their mechanism of action.
Development of such multidrug resistance (MDR) is a major
obstacle in the treatment of a variety of malignancies (Kaye,
1988). Although the altered expression of a number of pro-
teins has been associated with MDR in different model
systems, the overexpression of a 150-180 kDa glycoprotein
has been the most consistent. This glycoprotein, termed P-
glycoprotein, acts as an energy dependent efflux pump to
reduce drug accumulation within the cell (Gerlach et al.,
1986a). While overexpression of P-glycoprotein is clearly re-
sponsible for MDR in some cell systems, it is unlikely that
P-glycoprotein by itself can account for the plethora of
biochemical and genetic changes which occur as a cell adapts
to growth in the presence of antineoplastic agents (Kaye,
1988). The isolation of MDR cell lines which do not overex-
press P-glycoprotein, and the detection of P-glycoprotein in
only a subset of patients with drug-resistant tumours (Gold-
stein et al., 1989), support a multifactorial model of MDR
(Mirski et al., 1987; Danks et al., 1987; Slovak et al., 1988;
McGrath et al., 1989).
A number of monoclonal antibodies have been derived
with specificity for P-glycoprotein and have proven to be
valuable tools in the analysis of the MDR phenotype
mediated by P-glycoprotein (Kartner et al., 1985; Scheper et
al., 1988; Hamada & Tsuruo, 1988a, b; Thiebaut et al., 1987).
In the present study, we report the derivation of a mono-
clonal antibody against a MDR human ovarian carcinoma
cell line, A2780.AD (AD) (Rogan et al., 1984), which recog-
nises a cell surface antigen whose association with drug
resistance appears independent of P-glycoprotein.
A 6-8-week-old female Balb/c mouse was immunised with
four i.p. injections, each consisting of 10 x 106 viable AD
cells, on days 1, 7, 17 and 35 days. Four days following an
i.v. injection of 5 x 106 AD cells on day 59, the immune
spleen cells were fused with P3.NSI/Ag4.1 (NS-1) myeloma
cells using a 50% (w/v) polyethylene glycol solution (Ken-
nett, 1979). Hybrids were selected in hypoxanthine,
aminopterin and thymidine-containing medium and at 10- 14
days post-fusion, supernatants from wells containing macro-
scopically visible hybridomas were tested for specific anti-
bodies using an indirect enzyme-linked immunosorbent assay
(ELISA) with AD cells and the corresponding drug-sensitive
A2780-9S (9S) cells (Glassy & Surh, 1985; Mirski et al.,
1987). The criteria used to determine specific reactivity were:
(i) a ratio of absorbance values (A49 nm AD:A49 nm9S) greater
than 3; (ii) absorbance values on 9S cells similar to negative
control values; and (iii) consistent ELISA reactivity after
multiple passages in culture. Five hybridomas met these
criteria and were cloned by limiting dilution (Koziol et al.,
1987). Hybridomas were cryopreserved and 'supernatants
were collected and frozen at -20'C. One, designated MAb
7.4.1, was selected for further study; the antibody secreted by
this hybridoma was IgGI (Boehringer-Mannheim isotype kit).
The subcellular location of the epitope on AD cells recog-
nised by MAb 7.4.1 was determined by indirect
immunofluorescence. By fluorescence microscopy, MAb
7.4.1. labelled viable AD cells with high intensity and reacted
with the occasional 9S cell (less than 10%) (results not
shown), suggesting that since the antibody was reactive with
non-permeabilized cells, it detected a cell surface epitope. To
quantitate the degree of reactivity and to confirm the cell
surface location of the reactive epitope, flow cytometry was
performed (Figure 1). MAb 7.4.1 labelled 84% of the viable
AD cells, and only 1-2% of the 9S cells. The mean
fluorescence intensity observed with 9S cells was similar to
control values and was markedly less than that observed with
AD cells.
Since human tumour samples are frequently preserved by
fixation, it was of interest to determine whether formalin,
glutaraldehyde or methanol affected the epitope recognised
by MAb 7.4.1 (Table I). The antibody had reduced reactivity
in a cell ELISA on formalin fixed cells compared to unfixed
cells. Moreover, reactivity on cells fixed for 60 min was
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Figure 1 Flow cytometry following indirect immunofluorescence
labelling of 9S (-----) and AD ( ) cells with NS-1 myeloma
culture supernatant supplemented with irrelevant murine Igs (left
panel) or MAb 7.4.1 (right panel). Undiluted hybridoma culture
supernatant was added to 1 x 106 9S and AD cells at 4'C and
incubated for 60 min. The cells were washed and FITC-
conjugated goat anti-mouse Ig (G + A + M) diluted 1:25 was
added. After 60 min, the cells were washed and analysed using a
Becton-Dickinson fluorescence activated cell sorter (FACS) IV.
The excitation wavelength was 488 nm and the fluorescence
detector used a 530/20 nm bandpass filter. The instrument was
calibrated before each analysis using a standard suspension of
glutaraldehyde-fixed chicken erythrocytes. The frequency dis-
tribution of the relative fluorescence of a minimum of 10,000 cells
was obtained.
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Table I Effect of common fixatives on MAb 7.4.1 reactivity with
multidrug resistant human ovarian AD cellsa
Fixative Reactivit/
None + + +
Formalin
15 min +
60 min
Glutaraldehyde + +
Methanol + /-
aReactivity was assessed on fixed cells and compared to unfixed cells
in each experiment using the cell ELISA. For methanol fixation, cells
were resuspended in cold (-20C) 70% methanol for 5 min, washed,
resupended anddispensed into PVC microtest plates at 5 x 1O4cellsper
well anddehydrated at 37°C overnight. Forformalinfixation, cellswere
resuspended in buffered 3.7% formalin for either 15 or 60 min at room
temperature, washed andplated asdescribed formethanol fixation. For
glutaraldehyde fixation, cells were washed and 5 x 104 cells in 100ttl
PBS were dispensed into each well. Plates were centrifuged and 0.5%
glutaraldehyde in PBS (100 tlI perwell) was added and after 15 min, the
plates were washed. Unfixed AD cells were included in eachexperiment
as an internal standard for antibody reactivity. All experiments were
performed at least three times. bA490nm relative to unfixed cells: + + +,
75-100%; + +, 50-75% +, 25-50%; -, <25%.
diminished compared to cells fixed for only 15 min. MAb
7.4.1 retained approximately 60% of its reactivity on
glutaraldehyde fixed cells compared to control values
obtained with unfixed cells. The effect of methanol on MAb
7.4.1 reactivity varied from experiment to experiment,
although in most cases, reactivity was diminished 70-100%.
Thus, all three fixatives were found to adversely affect
antibody reactivity suggesting a limited potential of MAb
7.4.1 as an immunodiagnostic tool in vitro.
Immunoblotting experiments showed that MAb 7.4.1
reacts with three proteins of estimated molecular weights of
186, 169 and 158 kDa (Figure 2). No differences were
observed between samples tested under reducing and non-
reducing conditions. It is possible that the two smaller pro-
teins represent proteolytic breakdown products of the
186 kDa protein. However, this seems unlikely since protease
inhibitors were included in the lysis buffer used to prepare
cell extracts. A second possibility is that the difference bands
may reflect different degrees of glycosylation of a single
protein. Finally, it is also possible that MAb 7.4.1 recognises
a common epitope on three unrelated proteins. Further
investigation is required to determine which of these explana-
tions accounts for the multiplicity of bands observed. An
immunoblot performed under identical conditions but
incubated with MAb C219 against P-glycoprotein showed a
single broad band ofestimated molecular weight 168 kDa on
membrane preparations from AD cells (Figure 2).
The ability of MAb 7.4.1 to cross-react with other cell lines
was examined by indirect cell ELISA (Figure 3). The cell
lines tested included human cell lines H69, HT1080, WiDr
and 8226/S as well as the Chinese hamster ovary (CHO) cell
line Aux B1 and their respective drug-resistant variants, i.e.
H69AR (Mirski et al., 1987), HT1080/DR4 (Slovak et al.,
1988), WiDr/R (Dalton et al., 1988), 8226/R40 (Dalton et al.,
1986) and CHRC5 (Ling & Thompson, 1974). MAb 7.4.1
showed strong reactivity with both the drug-sensitive and
-resistant fibrosarcoma cell lines, HT1080 and HT1080/DR4.
Both colon carcinoma cell lines were also positive although
reactivity was considerably greater on the drug-resistant
WiDr/R than its sensitive parent. No reactivity was observed
with the myeloma cell lines, 8226/S and 8226/R40, the CHO
cell lines, Aux Bi and CHRC5, nor the small cell lung
tumour cell lines, H69 and H69AR. Lastly, MAb 7.4.1 did
not cross-react with peripheral blood lymphocytes (results
not shown).
In summary, three lines of evidence indicate that MAb
7.4.1 recognises an antigen distinct from P-glycoprotein.
Firstly, its pattern of reactivity on immunoblots is quite
distinct from that of MAb C219 which is directed towards a
highly conserved epitope of P-glycoprotein. Secondly, MAb
AD 9S
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Figure 2 Immunoblot of membrane preparations with MAb
7.4.1 (left panel) and MAb C219 (right panel). Molecular weight
markers are indicated between the panels. Membrane fractions of
9S and AD cells were prepared as described by Gerlach et al.
(1987) and protein concentration determined (Peterson, 1977).
Forty ytg of protein was subjected to sodium dodecyl sulphate
polyacrylamide gel electrophoresis (Laemmli, 1970) and the gel
was replica-blotted onto Immobilon (Millipore) by the method of
Towbin et al. (1979). The blot was incubated with MAb 7.4.1 and
binding of antibody was detected with alkaline phosphatase-
conjugated goat anti-mouse IgG (Jackson Immuno Research
Laboratories, West Grove, PA) with nitroblue tetrazolium and
bromochloro-indolyl phosphate as substrates (Mierendorf et al.,
1987). For detection' of P-glycoprotein, 120gg of protein from
the membrane fraction of AD cells was electrophoresed and
blotted as above and the blot incubated with 125 ng ml-' MAb
C219 (Centocor, Malvern, PA) and binding detected as for MAb
7.4.1.
7.4.1 does not cross-react with CHRC5 and 8226/Dox cells,
which are known to overexpress P-glycoprotein (Ling &
Thompson, 1974; Dalton et al., 1986). Thirdly, MAb 7.4.1
has significant reactivity with two drug-resistant cell lines,
WiDr/R and HT1080/DR4, in which enhanced expression of
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Figure 3 Cross-reactivity of MAb 7.4.1 with paired drug-
sensitive (open bars) and resistant (filled bars) cell lines as
determined by cell ELISA. The results shown are the mean of
duplicate determinations in a single experiment. Similar results
were obtained in at least one additional experiment.
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P-glycoprotein is not detectable (Dalton et al., 1988; Slovak
et al., 1988). WiDr/R is a mitoxantrone-selected drug-
resistant colon carcinoma cell line which does not exhibit the
MDR phenotype, as it is commonly defined (Gerlach et al.,
1986b), since it displays only marginal cross-resistance to the
Vinca alkaloids (Dalton et al., 1988). Nevertheless, the
antigen(s) defined by MAb 7.4.1 is overexpressed on this
resistant cell line compared to its parent cell line. By contrast,
MAb 7.4.1 is only slightly more reactive with drug-resistant
fibrosarcoma cell line, HT1080/DR4, compared to its parent
cell line, HT1080. One interpretation of these results is that
the MAb 7.4.1-defined antigen(s) may be only one of several
factors mediating drug resistance in these cell lines. Whether
this antibody detects the same set of proteins on the HT1080
and WiDr/R cell lines is currently under investigation. It
should be noted that this antigen is not invariably associated
with non-P-glycoprotein-mediated drug resistance since it is
not found on the MDR small cell lung cancer cell line,
H69AR (Mirski et al., 1987). Clearly much work remains to
be done to determine what role, if any, the antigen(s) defined
by MAb 7.4.1 plays in drug resistance.
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